Amicus Therapeutics Inc (FOLD)

6.09
NASDAQ : Health Care
Prev Close 6.05
Day Low/High 5.98 / 6.43
52 Wk Low/High 4.98 / 10.00
Avg Volume 2.52M
Exchange NASDAQ
Shares Outstanding 142.33M
Market Cap 861.07M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

FOLD Makes Notable Cross Below Critical Moving Average

FOLD Makes Notable Cross Below Critical Moving Average

In trading on Tuesday, shares of Amicus Therapeutics Inc crossed below their 200 day moving average of $7.13, changing hands as low as $6.30 per share. Amicus Therapeutics Inc shares are currently trading off about 22.2% on the day.

Futures Flat as Investors Take Profits; Asia Mixed

Futures Flat as Investors Take Profits; Asia Mixed

Futures remain soft, but analysts believe rally still has steam.

Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan

Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan

The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.

4 Promising Small Biotechs to Watch in 2017

4 Promising Small Biotechs to Watch in 2017

Veterinary drug play Aratana Therapeutics is among the potential solid performers next year.

First Week of FOLD July 2017 Options Trading

First Week of FOLD July 2017 Options Trading

Investors in Amicus Therapeutics Inc saw new options become available this week, for the July 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Amicus Therapeutics Becomes Oversold (FOLD)

Amicus Therapeutics Becomes Oversold (FOLD)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of December 16th Options Trading For Amicus Therapeutics (FOLD)

First Week of December 16th Options Trading For Amicus Therapeutics (FOLD)

Investors in Amicus Therapeutics Inc saw new options become available this week, for the December 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FOLD options chain for the new December 16th contracts and identified one put and one call contract of particular interest.

Amicus Therapeutics (FOLD) Shares Cross Below 200 DMA

Amicus Therapeutics (FOLD) Shares Cross Below 200 DMA

In trading on Friday, shares of Amicus Therapeutics Inc crossed below their 200 day moving average of $7.01, changing hands as low as $6.89 per share. Amicus Therapeutics Inc shares are currently trading off about 4.6% on the day.

TG Therapeutics Looks Like a Healthy Play

TG Therapeutics Looks Like a Healthy Play

Small biotech tanked on weak earnings, but still seems promising.

3 Biotech-Investing Mistakes to Avoid

3 Biotech-Investing Mistakes to Avoid

These are the biggest errors that I've made over the years.

Amicus (FOLD) CEO Crowley to CNBC: 'Our Job is to Stay Focused and Keep Making Great Medicines'

Amicus (FOLD) CEO Crowley to CNBC: 'Our Job is to Stay Focused and Keep Making Great Medicines'

Amicus Therapeutics (FOLD) CEO John Crowley joined Thursday morning's 'Squawk Box' on CNBC to discuss the future of the company and new medications in the pipeline.

Amicus Therapeutics (FOLD) Stock Slumps on Q2 Loss

Amicus Therapeutics (FOLD) Stock Slumps on Q2 Loss

Amicus Therapeutics (FOLD) reported a wider-than-expected loss for the 2016 second quarter before Tuesday's market open.